Research Paper Volume 15, Issue 12 pp 5650—5661
Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma
Figure 7. Relationship between the immune prognostic model (IPM) and other clinical information. (A) Univariate and multivariate regression analyses of the relationship between the IPM and clinicopathological features regarding prognostic value. (B) Nomogram for predicting the probability of 1-, 3-, and 5-year overall survival (OS) in lung adenocarcinoma (LUAD) patients. (C) Calibration plot of the nomogram for predicting the probability of OS at 1, 3, and 5 years.